SNSE

Sensei Biotherapeutics Inc

Feb 26 • 04:00PM ET

30.22

-4.01 -11.71 %

Healthcare • Biotechnology • USA • NASD

Peers: XNCR ADAP CLLS FATE CRSP VIVS ACHL BNTX BLUE

Index	-	P/E	-	EPS (ttm)	-21.31	Insider Own	31.99%	Shs Outstand	1.26M	Perf Week	11.02%
Market Cap	38.12M	Forward P/E	-	EPS next Y	-	Insider Trans	-12.15%	Shs Float	0.86M	Perf Month	204.02%
Enterprise Value	12.05M	PEG	-	EPS next Q	-	Inst Own	13.85%	Short Float	3.02%	Perf Quarter	236.57%
Income	-26.82M	P/S	-	EPS this Y	-	Inst Trans	-0.12%	Short Ratio	0.08	Perf Half Y	285.84%
Sales	0.00M	P/B	1.40	EPS next Y	-	ROA	-58.58%	Short Interest	0.03M	Perf YTD	183.22%
Book/sh	21.66	P/C	1.33	EPS next 5Y	-	ROE	-67.47%	52W High	36.76 -17.79%	Perf Year	233.63%
Cash/sh	22.70	P/FCF	-	EPS past 3/5Y	3.30% -11.38%	ROIC	-96.11%	52W Low	5.00 504.40%	Perf 3Y	2.79%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	19.95% 12.62%	Perf 5Y	-90.84%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	9.63%	Oper. Margin	-	ATR (14)	3.50	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	7.64	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	74.18	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	7.64	EPS Q/Q	31.20%	SMA20	79.46%	Beta	-0.03	Target Price	30.00
Payout	-	Debt/Eq	0.09	Sales Q/Q	-	SMA50	137.15%	Rel Volume	0.74	Prev Close	34.23
Employees	15	LT Debt/Eq	0.02	Earnings	Nov 14 BMO	SMA200	215.72%	Avg Volume	321.44K	Price	30.22
IPO	Feb 04, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	11.92% -	Trades		Volume	235,804	Change	-11.71%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-02-25	Resumed	H.C. Wainwright	Buy	$5
May-14-24	Initiated	Stephens	Overweight	$5
Jul-01-21	Downgrade	Berenberg	Buy → Hold	$12
Jun-29-21	Downgrade	Oppenheimer	Outperform → Perform	$30 → $14
Mar-01-21	Initiated	Piper Sandler	Overweight	$25
Mar-01-21	Initiated	Oppenheimer	Outperform	$36
Mar-01-21	Initiated	Citigroup	Buy	$30
Mar-01-21	Initiated	Berenberg	Buy	$27

Feb-25-26 06:00AM	Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-18-26 12:09PM	Sensei Biotherapeutics Stock Soars 230% After Faeth Deal (Benzinga) +187.51%
08:00AM	Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement (Business Wire)
Nov-14-25 07:30AM	Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results (GlobeNewswire) -11.25%
Oct-31-25 02:06PM	Sensei to ditch its lead candidate and cut workforce amidst strategic review (Pharmaceutical Technology)
09:00AM	Loading…
Oct-30-25 09:00AM	Sensei Biotherapeutics Announces Initiation of Strategic Review to Maximize Shareholder Value (GlobeNewswire)
Oct-17-25 08:00AM	Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025 (GlobeNewswire) -33.43%
Sep-23-25 07:30AM	Sensei Biotherapeutics to Host Virtual KOL Event to Discuss Full Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors on October 20, 2025 (GlobeNewswire)
Sep-03-25 08:00AM	Sensei Biotherapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire) +10.57%
Aug-05-25 07:30AM	Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-30-25 07:30AM	Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025 (GlobeNewswire) +7.50%
Jun-13-25 07:30AM	Sensei Biotherapeutics Announces 1-for-20 Reverse Stock Split (GlobeNewswire) -10.58%
May-06-25 07:30AM	Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress (GlobeNewswire) -5.29%
Apr-02-25 07:30AM	Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference (GlobeNewswire) +6.09%
Mar-28-25 07:30AM	Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress (GlobeNewswire) +17.99%
04:05PM	Loading…
Mar-27-25 04:05PM	Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors (GlobeNewswire)
Feb-06-25 12:00PM	What Makes Sensei Biotherapeutics (SNSE) a New Buy Stock (Zacks)
Feb-04-25 07:30AM	Sensei Biotherapeutics to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-08-25 07:30AM	Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones (GlobeNewswire)
Nov-27-24 04:05PM	Sensei Biotherapeutics to Participate in Citi's 2024 Global Healthcare Conference (GlobeNewswire)
Nov-14-24 07:30AM	Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire) -13.06%
Oct-29-24 07:30AM	Sensei Biotherapeutics to Present at Two Upcoming Scientific Conferences (GlobeNewswire)
Sep-04-24 04:05PM	Sensei Biotherapeutics to Present Preclinical Data on SNS-103 at the CRI-ENCI Eighth International Immunotherapy Conference (GlobeNewswire)
07:30AM	Sensei Biotherapeutics to Present at Upcoming Conferences (GlobeNewswire)
Aug-06-24 01:53PM	SNSE Stock Earnings: Sensei Biotherapeutics Beats EPS for Q2 2024 (InvestorPlace) +6.56%
07:30AM	Sensei Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
May-30-24 07:30AM	Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference (GlobeNewswire) -11.07%
May-24-24 08:27AM	Why Is Sensei Biotherapeutics (SNSE) Stock Down 40% Today? (InvestorPlace) -45.52%
07:16AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
May-23-24 05:10PM	Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101 (GlobeNewswire) +6.62%
01:54PM	Loading…
May-09-24 01:54PM	SNSE Stock Earnings: Sensei Biotherapeutics Misses EPS for Q1 2024 (InvestorPlace) -14.67%
07:30AM	Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Apr-24-24 04:05PM	Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting (GlobeNewswire)
Apr-09-24 07:30AM	Sensei Biotherapeutics to Participate in Canaccord Genuity's Horizons in Oncology Virtual Conference (GlobeNewswire) +6.28%
Apr-04-24 04:05PM	Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment (GlobeNewswire)
Mar-22-24 07:30AM	Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium (GlobeNewswire) +11.43%
Mar-06-24 07:30AM	Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences (GlobeNewswire)
Feb-28-24 07:30AM	Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights (GlobeNewswire) +9.09%
Feb-07-24 07:30AM	Sensei Biotherapeutics to Present at Upcoming Conferences (GlobeNewswire) +6.12%
Jan-04-24 07:30AM	Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones (GlobeNewswire)
Nov-07-23 08:09AM	Sensei Biotherapeutics Inc (SNSE) Reports Q3 2023 Financial Results (GuruFocus.com) -7.15%
07:30AM	Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Nov-03-23 04:05PM	Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meeting (GlobeNewswire) -13.75% +9.42%
Nov-01-23 07:30AM	Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business Officer (GlobeNewswire) +15.33%
Oct-25-23 09:05AM	Sensei Biotherapeutics to Present Initial Clinical Data from Dose Escalation Trial of SNS-101 at 2023 SITC Annual Meeting (GlobeNewswire)
Oct-23-23 07:30AM	Sensei Biotherapeutics Presents Trial-in-Progress Poster for Phase 1/2 Clinical Study of SNS-101 at ESMO 2023 (GlobeNewswire)
Sep-27-23 07:30AM	Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron s Libtayo (GlobeNewswire) -10.17%
Sep-21-23 07:30AM	Sensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference (GlobeNewswire)
Sep-13-23 07:30AM	Sensei Biotherapeutics to Present New Preclinical Data Supporting Mechanism of Action, Pharmacokinetic Profile and Safety Characteristics for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference (GlobeNewswire)
Aug-30-23 07:30AM	Sensei Biotherapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-19-23 10:44AM	Billionaire Stan Druckenmillers Small-Cap Stock Picks (Insider Monkey)
Aug-03-23 07:30AM	Sensei Biotherapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Aug-02-23 07:30AM	Sensei Biotherapeutics to Participate in Canaccord Genuitys 43rd Annual Growth Conference (GlobeNewswire)
Jun-13-23 07:30AM	Sensei Biotherapeutics to Host Virtual Key Opinion Leader Event, A New Vista for Cancer Care: Exploring SNS-101s Potential as a Transformative Treatment Option for Patients with Solid Tumors (GlobeNewswire)
Jun-01-23 07:30AM	Sensei Biotherapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-101, a Conditionally Active VISTA-blocking Antibody, for the Treatment of Advanced Solid Tumors (GlobeNewswire)
May-31-23 07:30AM	Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference (GlobeNewswire)
May-09-23 07:30AM	Sensei Biotherapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Apr-20-23 07:30AM	Sensei Biotherapeutics Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for SNS-101, a Conditionally Active VISTA-Blocking Antibody (GlobeNewswire)
Apr-18-23 04:05PM	Sensei Biotherapeutics Presents New Preclinical Data on SNS-103 Targeting ENTPDase1 (CD39) at the American Association for Cancer Research (AACR) Annual Meeting 2023 (GlobeNewswire)
Apr-13-23 07:30AM	Sensei Biotherapeutics to Participate in Canaccord Genuitys Horizons in Oncology Virtual Conference (GlobeNewswire)
Mar-30-23 07:30AM	Sensei Biotherapeutics to Participate in Cantor Fitzgeralds Future of Oncology Virtual Symposium (GlobeNewswire) +6.11%
Mar-28-23 07:30AM	Sensei Biotherapeutics Reports Full Year 2022 Financial Results and Recent Business Highlights (GlobeNewswire)
Mar-23-23 11:56AM	Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation (Simply Wall St.)
Mar-21-23 07:30AM	Sensei Biotherapeutics Announces Submission of Investigational New Drug (IND) Application for SNS-101, a Conditionally Active VISTA-Blocking Antibody (GlobeNewswire)
Mar-14-23 04:35PM	Sensei Biotherapeutics to Present New Preclinical Data for SNS-103, a Conditionally Active Monoclonal Antibody Targeting ENTPDase1 (CD39), at the American Association for Cancer Research (AACR) Annual Meeting 2023 (GlobeNewswire) +9.92%
Mar-07-23 05:15PM	Sensei Biotherapeutics Adopts Stockholder Rights Agreement (GlobeNewswire) +6.49%
Mar-06-23 07:30AM	Sensei Biotherapeutics to Participate in Oppenheimers 33rd Annual Healthcare Conference (GlobeNewswire)
Feb-21-23 07:30AM	Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics (GlobeNewswire) -7.14%
Feb-16-23 07:30AM	Sensei Biotherapeutics to Participate in Citis 2023 Virtual Oncology Leadership Summit (GlobeNewswire)
Feb-14-23 07:30AM	Sensei Biotherapeutics to Present New Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics (GlobeNewswire)
Feb-06-23 07:30AM	Sensei Biotherapeutics Signs Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to Expand Development Plan for SNS-101, a Conditionally Active VISTA-blocking Antibody (GlobeNewswire)
Jan-05-23 07:30AM	Sensei Biotherapeutics Announces Clinical Supply Agreement with Regeneron for Phase 1/2 Clinical Trial Evaluating SNS-101, a Conditionally Active VISTA-blocking Antibody, in Combination with Libtayo® (cemiplimab) in Solid Tumors (GlobeNewswire)
Dec-08-22 01:10PM	Immunotherapy startup shutters Boston research site, lays off 17 (American City Business Journals)
10:40AM	Sensei Biotherapeutics Slashes Workforce, Closes R&D Site (Benzinga)
07:30AM	Sensei Biotherapeutics Provides Update on Strategic Priorities (GlobeNewswire)
Nov-22-22 07:30AM	Sensei Biotherapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference (GlobeNewswire)
Nov-21-22 07:30AM	Sensei Biotherapeutics Announces Collaboration with Washington University, St. Louis to Support Development of SNS-101, a Conditionally Active VISTA-blocking Antibody (GlobeNewswire)
06:00AM	Significant Investor in Sensei Biotherapeutics, Inc. Urges Board to Seek Shareholder Mandate (GlobeNewswire)
Nov-10-22 09:00AM	Sensei Biotherapeutics Presents Preclinical Data at the 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire) +9.49%
Nov-08-22 07:30AM	Sensei Biotherapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights (GlobeNewswire)
Nov-07-22 07:30AM	Sensei Biotherapeutics to Host Virtual Key Opinion Leader Webinar, Lessons from VISTA: New Strategies to Address an Important Immune Checkpoint (GlobeNewswire)
Nov-02-22 07:30AM	Sensei Biotherapeutics to Participate in the 13th Annual Jefferies Global Healthcare Conference (GlobeNewswire)
Oct-14-22 10:22AM	We're Keeping An Eye On Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Rate (Simply Wall St.)
Oct-05-22 08:05AM	Sensei Biotherapeutics to Present New Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting (GlobeNewswire)
Sep-30-22 04:05PM	Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival (GlobeNewswire) +7.10%
Sep-21-22 04:05PM	Sensei Biotherapeutics to Present Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival (GlobeNewswire) -5.32%
Aug-31-22 07:30AM	Sensei Biotherapeutics Announces New Preclinical Data Demonstrating Favorable Pharmacokinetic and Immunologic Effects of SNS-101, a pH-selective VISTA-blocking Antibody (GlobeNewswire)
Aug-23-22 07:30AM	Sensei Biotherapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-11-22 07:02AM	One Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) insider upped their stake by 13% in the previous year (Simply Wall St.)
Aug-09-22 07:30AM	Sensei Biotherapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights (GlobeNewswire) -5.37%
Jun-01-22 07:30AM	Sensei Biotherapeutics Appoints Patrick Gallagher, MBA, MPH, as Chief Business Officer (GlobeNewswire)
May-25-22 07:30AM	Sensei Biotherapeutics to Participate in Jefferies Healthcare Conference (GlobeNewswire) -6.32%
May-10-22 07:30AM	Sensei Biotherapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights (GlobeNewswire) +9.80%
May-07-22 09:40AM	Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation (Simply Wall St.)
Apr-21-22 09:09AM	9 Healthcare Stocks to Invest In Today According to Stanley Druckenmiller (Insider Monkey)
Mar-10-22 07:30AM	Sensei Biotherapeutics Reports Full Year 2021 Financial Results and Business Highlights (GlobeNewswire) -7.62%
Mar-09-22 04:05PM	Sensei Biotherapeutics Appoints William Ringo, MBA, as Chair of Board of Directors (GlobeNewswire) +6.49%
Mar-03-22 07:30AM	Sensei Biotherapeutics to Participate in the 32nd Annual Oppenheimer Healthcare Conference (GlobeNewswire) -5.36%
Feb-11-22 07:30AM	Sensei Biotherapeutics to Participate in Citis 2022 Virtual Immuno-Oncology Summit (GlobeNewswire)
Jan-17-22 11:22AM	Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) insiders placed bullish bets worth US$1.0m in the last 12 months (Simply Wall St.)

Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company was founded in 1999 and is headquartered in Rockville, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Celebi John	Former Officer	Feb 24 '26	Proposed Sale	34.49	3,374	116,356		Feb 24 04:11 PM
Peyer James	Fomer Director	Feb 18 '26	Proposed Sale	27.13	950	25,769		Feb 18 01:22 PM
RINGO WILLIAM R	Former Director	Jan 27 '26	Proposed Sale	9.83	1,169	11,486		Jan 27 05:33 PM
Cambrian BioPharma Inc	10% Owner	Dec 09 '25	Option Exercise	6.40	395	2,528	155,983	Dec 10 04:56 PM
Cambrian BioPharma Inc	10% Owner	Dec 09 '25	Sale	8.25	6,612	54,575	155,142	Dec 10 04:56 PM
Peyer James	10% Owner	Dec 09 '25	Option Exercise	6.40	395	2,528	155,983	Dec 10 04:52 PM
Peyer James	10% Owner	Dec 09 '25	Sale	7.96	3,507	27,903	155,142	Dec 10 04:52 PM
Peyer James	10% Owner	Dec 08 '25	Sale	8.59	3,105	26,672	158,254	Dec 10 04:52 PM
Peyer James	Former Director	Dec 09 '25	Proposed Sale	7.97	841	6,707		Dec 09 12:20 PM
Cambrian BioPharma Inc	10% Owner	Dec 05 '25	Sale	11.50	16,295	187,390	161,359	Dec 08 04:39 PM
Cambrian BioPharma Inc	10% Owner	Dec 04 '25	Sale	9.06	5,000	45,300	177,654	Dec 08 04:39 PM
Peyer James	10% Owner	Dec 05 '25	Sale	11.50	16,295	187,390	161,359	Dec 08 04:36 PM
Peyer James	10% Owner	Dec 04 '25	Sale	9.06	5,000	45,300	177,654	Dec 08 04:36 PM
Cambrian BioPharma Inc	10% Owner	Dec 04 '25	Proposed Sale	8.71	5,844	50,901		Dec 04 04:18 PM
Cambrian BioPharma Inc	10% Owner	Dec 04 '25	Proposed Sale	8.71	21,222	184,843		Dec 04 03:41 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SNSE

Sensei Biotherapeutics Inc

Upgrade your FINVIZ experience